Here are the 10-K annual reports from Zenas BioPharma, Inc. (ZBIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBIO filings page.
Zenas BioPharma presents a detailed 10-K describing its immunology-focused pipeline, led by obexelimab and orelabrutinib. Obexelimab, a bifunctional anti-CD19/FcγRIIb antibody, showed a 56% reduction in IgG4-related disease flare risk versus placebo in the Phase 3 INDIGO trial and is moving toward BLA and MAA submissions in 2026.
In relapsing multiple sclerosis, the Phase 2 MoonStone study showed a 95% relative reduction in new gadolinium-enhancing T1 lesions at weeks 8–12 versus placebo, with effects maintained through week 24 and a 40% drop in serum NfL. Zenas also highlights a broad early-stage I&I portfolio (including orelabrutinib, ZB021, ZB022, ZB002 and ZB004) plus regional programs and licensing deals with Xencor, InnoCare, Viridian, Zai Lab and Tenacia. The company has no approved products and no product sales to date.